메뉴 건너뛰기
Lancet
Volumn 352, Issue 9142, 1998, Pages 1751-1752
Fatal interaction between ritonavir and MDMA
Author keywords

[No Author keywords available]
Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; RITONAVIR;
EID: 0032576351     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(05)79824-X     Document Type: Article
Times cited : (115)
References (5)
  • 1
    • 0026680529 scopus 로고
    • Toxicity and deaths from 3, 4-methylenedioxymethamphetamine ("ecstasy")
    • 1 Henry JA, Jeffreys KJ, Bawling S. Toxicity and deaths from 3, 4-methylenedioxymethamphetamine ("ecstasy"). Lancet 1992; 340: 384-87.
    • (1992) Lancet , vol.340 , pp. 384-387
    • Henry, J.A.1    Jeffreys, K.J.2    Bawling, S.3
  • 2
    • 0027998706 scopus 로고
    • Survival following intentional massive overdose of "Ecstasy"
    • 2 Roberts L, Wright H. Survival following intentional massive overdose of "Ecstasy". J Accid Emerg Med 1993; 11: 53-54.
    • (1993) J Accid Emerg Med , vol.11 , pp. 53-54
    • Roberts, L.1    Wright, H.2
  • 3
    • 0030895312 scopus 로고    scopus 로고
    • Protease inhibitors in patients with HIV disease: Clinically important pharmacokinetic considerations
    • 3 Barry M, Gibbons S, Black D, Mulcahy F. Protease inhibitors in patients with HIV disease: clinically important pharmacokinetic considerations. Clin Pharmacokinet 1997; 32: 194-209.
    • (1997) Clin Pharmacokinet , vol.32 , pp. 194-209
    • Barry, M.1    Gibbons, S.2    Black, D.3    Mulcahy, F.4
  • 4
    • 0028178550 scopus 로고
    • The demethylenation of methylenedioxymethamphetamine ("Ecstasy") by debrisoquine hydroxylase (CYP2D6)
    • 4 Tucker GT, Lannard MS, Ellis SW, et al. The demethylenation of methylenedioxymethamphetamine ("Ecstasy") by debrisoquine hydroxylase (CYP2D6). Biochem Pathol 1994; 47: 1151-56.
    • (1994) Biochem Pathol , vol.47 , pp. 1151-1156
    • Tucker, G.T.1    Lannard, M.S.2    Ellis, S.W.3
  • 5
    • 0024359574 scopus 로고
    • Clinical significance of sparteine/debrisoquine oxidation polymorphism
    • 5 Brosen K, Gram LF. Clinical significance of sparteine/debrisoquine oxidation polymorphism. Eur J Clin Pharmacol 1989; 36: 537-47.
    • (1989) Eur J Clin Pharmacol , vol.36 , pp. 537-547
    • Brosen, K.1    Gram, L.F.2

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.